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To evaluate the feasibility, effectiveness, and long-term bowel function of preoperative hyperfractionated accelerated radiotherapy in
primary resectable rectal cancer. A total of 184 consecutive patients (median age 65 years, male:female¼2:1) with clinical T3Nx
rectal adenocarcinoma received preoperative pelvic radiation therapy with single fractions of 2.5Gy twice daily (interval 6h between
fractions) to a total dose of 25Gy within 1 week. Surgery was conducted the following week. Postoperative histology revealed UICC
stage I in 33%, stage II in 26%, stage III in 34%, and stage IV in 7% of the patients. Median follow-up was 43 months (53 months for
surviving patients). The actuarial 4-year-local-recurrence rate was 2.1%, overall recurrence 23%. Disease-specific and disease-free
survivals at 4 years (excluding stage IV) were 82 and 69%, respectively. Overall survival for 4 years was 68%. Postoperative mortality
was 0.5% (one patient), early anastomotic leakage occurred in 11.4%, and anastomotic stenosis requiring treatment in 6%, of 132
patients with primary anastomosis. Seven of 184 patients (3.8%) died of abdominal complications, all within the first year. Bowel
function was satisfactory after more than 5 years. Local control in primarily resectable rectal cancer after 10 2.5Gy is excellent,
warranting further evaluation of this treatment.
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Local tumour control remains an important aim in the treatment
of rectal cancer because of devastating morbidity and unsatisfac-
tory treatment options for local recurrence (Esnaola et al, 2002).
Surgical advances in recent years have led to a significant
reduction of local recurrences particularly due to standardised
introduction of total mesorectal excision (TME) (MacFarlane et al,
1993). Independently, neo-adjuvant or adjuvant radiotherapy
reduces the incidence of local relapse by 50% as shown by meta-
analyses (Camma et al, 2000; Colorectal Cancer Collaborative
Group, 2001). The positive effect of radiation is maintained even
with quality-controlled TME surgery (Kapiteijn et al, 2001).
Preoperative radiation therapy using 25Gy with daily fractions
of 5Gy, administered within 1 week with surgery performed
during the following week, is a widely tested treatment regimen. Its
efficacy regarding prevention of local recurrence has been
documented in several thousand patients (Glimelius, 2002) and it
has been shown to increase the overall survival by 10% in one large
trial (Swedish Rectal Cancer Trial, 1997). Nevertheless, concern
remains within the oncology community regarding the daily 5Gy
dose per fraction. We have therefore introduced a modification of
the 5 5Gy treatment regimen at our department in 1994. The
total dose of 25Gy is given by single fractions of 2.5Gy delivered
twice daily with an interfraction interval of at least 6h, whereby the
overall treatment time of 1 week is maintained. Sufficient recovery
of normal tissue after 6h has been shown to occur in several
clinical situations so that late reactions are not expected to increase
compared to conventional fractionation (Dische et al, 1997). Thus,
the low total dose of 25Gy is predicted to translate into a low
probability of negative late adverse effects (see Appendix A).
We report the efficacy, toxicity, and long-term functional results
of the first 184 consecutive patients treated between 1994 and 2000
with this new regimen at the Department of Radiotherapy and
Radiobiology at Medical University of Vienna General Hospital.
PATIENTS AND METHODS
Patients with histologically proven adenocarcinoma of the rectum
without evidence of distant metastases were eligible, if transmural
extension was to be expected upon digital examination, recto-
scopy, and pelvic computed tomography (CT) scan. Pelvic MRI
was not used for staging. A complete resection of all tumour tissue,
either by low anterior resection (LAR) with primary anastomosis
or by abdominoperineal resection (APR), was to be judged feasible
by an experienced rectal surgeon. Patients with large T3 tumours,
where a radical resection appeared to be uncertain due to
adherence to the pelvic side-wall, to the presacral fascia, or to
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sadjacent organs, or patients with obvious T4 tumours received
long-term preoperative radiochemotherapy with downsizing intent
and are not included in this analysis. Patients with suspected T1/
T2 tumours upon clinical and radiological evaluation without
evidence of positive lymph nodes were not referred for radio-
therapy, as were patients who had undergone previous pelvic
radiotherapy for other reasons. Synchronous tumours in the colon
were ruled out by colonoscopy or by barium enema, distant
metastases by CT scans of the chest and abdomen.
Patients provided written informed consent upon participation
and the protocol was approved by the institutional review board of
Vienna Medical University.
Follow-up was every 3 months during the first year post-
treatment, every 6 months during the second and third years, and
yearly thereafter. Clinical evaluation was supported by checking
tumour markers CEA and CA 19-9, abdominal-pelvic CT scans or
MRI, and chest X-ray as appropriate. In cases of rising tumour
markers, a complete screening for recurrence was performed.
Suspicious intrapelvic tissue was followed by CT or MRI and
histological exploration was performed in cases of remaining
uncertainty. Bowel function was assessed in 2003 and 2004 for
patients treated in 1994–1998.
Radiotherapy
The clinical target volume comprised the tumour, the mesorectal
tissue including perirectal and presacral nodes, and internal iliac
lymph nodes (Widder et al, 2000). The caudal boundary of the
clinical target volume was at 5cm caudal to the macroscopic
tumour as assessed by rectoscopy, digital rectal, and fluoroscopic
investigation using a small rectal barium enema at simulation.
Therefore, the anus was included only in very low tumours where a
safety margin could not otherwise be obtained. The perineum was
not included in the target volume even if an APR was planned.
Patients were simulated in prone position with full bladder and
barium enema of the small intestine. They were treated using a
four-field box technique from 1994 to early 1997, and with three
fields (same target volume) with a posterior and two lateral
opposing wedged fields thereafter. Individual shielding was
obligatory by individual shielding blocks or multileaf collimation.
Single doses per fraction were 2.5Gy calculated at the ICRU
(1993) point. Fractions were delivered with 6 or 10MeV photons
for the posterior portal, and with 25MeV for the anterior (if used)
and the lateral portals. Wedges to increase dose homogeneity were
calculated on the basis of at least three relevant CT sections. Two
fractions with intervals between fractions of at least 6h were
delivered every day from Monday to Friday to result in a total dose
of 25Gy within 1 week.
Surgery
Surgery was planned within 1 week after radiotherapy. Employing
a midline laparotomy, the splenic flexure was mobilised routinely
with high ligation of inferior mesenteric vein and artery. Following
sharp perimesorectal dissection, the rectum was divided at least
2cm and the mesorectum at least 5cm below the tumour. This
resulted in a TME operation for all tumours located in the middle
and lower thirds of the rectum, respectively. Only for lesions in the
upper third a partial mesorectal excision was employed. Abdom-
inal dissection was identical for patients undergoing an APR. More
than 90% of the anastomoses were stapled; the remainders were
hand-sewn. Short colon-J-pouches were added at the discretion of
the operating surgeon, as were diverting ostomies.
Bowel function
Bowel function was assessed at the last follow-up later than 5 years
after treatment. Assessment was conducted by the doctor in the
outpatient clinic or by telephone by directly inquiring the
following items: (1) frequency of bowel emptying per day: one or
less/two to three/more than three. (2) Clustering: one portion/two
to three portions/more than three portions. (3) Ability to delay
defecation upon urge: more than 15min/less than 15min. (4)
Ability to distinguish between stool and gas: yes/no. (5) Experien-
cing tenesms: no/yes. (6) Wearing pads: no/yes. (7) Experiencing
pelvic pain: no/yes. (8) Quality of life altered because of bowel
function: no/yes/significantly.
Statistics
Survival and recurrence data were calculated by the Kaplan–Meier
method using SPSS statistical software (SPSS, Chicago, version 8.0
for Windows). Recurrence, overall, disease-specific, and disease-
free survivals were assessed for all patients and for patients
without primary metastases (stages I–III), respectively. Results for
UICC stages were compared using the log-rank statistic. Of note,
local recurrence was assessed by counting any local recurrence as
event, regardless of whether this occurred as first recurrence or
after metastasis. Patients who had not undergone a macroscopi-
cally complete tumour resection (four patients) were not
assessable for local failure because they were never rendered free
of local tumour. Nevertheless, actuarial local control for all
patients including those incompletely resected is also reported.
RESULTS
Patients
From February 1994 to December 2000, 184 patients with
histologically proven adenocarcinoma of the rectum with clinical
or radiological (CT) signs of transmural extension or with
suspicious pelvic lymph nodes were referred for radiotherapy.
This report includes the results of a consecutive cohort of patients
Table 1 Tumour characteristics
Postoperative n %
UICC stages
Stage I 60 33
Stage II 48 26
Stage III 63 34
Stage IV 13 7
Total 184 100
pTNM (%) N0 N1–2 Total
T1 6 0.5 6.5
T2 27 8 (0.5)
a 34 (0.5)
a
T3 26 (0.5)
a 29 (5)
a 55 (6)
a
T4 0.5 3 (0.5)
a 4 (0.5)
a
Total 59 (0.5)
a 41 (7)
a 100 (7)
a
Surgery n (%) AKH-DoS Other DoS
SSR 132 (72) 81 (81)* 51 (61)*
APR 48 (26) 17 (17) 31 (37)
Other 4 (2) 2 (2) 2 (2)
184 (100) 100 (100) 84 (100)
aNumbers in parentheses represent percentage of patients with metastases,
encountered at surgery. *Po0.05 (w
2 test) for SSR, AKH-DoS vs other DoS. SSR:
sphincter-sparing resection; APR: abdominoperineal resection; AKH-DoS: Depart-
ment of Surgery, Vienna Medical University General Hospital; other DoS:
Department of Surgery, other institution.
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swithout proven distant metastases prior to treatment, who seemed
primarily amenable to curative oncological surgery.
In all, 65% of the patients were men, 35% women; median age
was 65 years (range 32–89). Postoperative UICC and pTNM stages,
and types of surgery are displayed in Table 1. A total of 61% of the
tumours were located in the lower third of the rectum, 29% in the
middle third, and 10% in the upper third.
Radiotherapy and surgery
An amount of 25Gy was given with single doses of 2.5Gy twice
daily with interfraction intervals of 6 or more hours on five
consecutive days without breaks (Monday–Friday) as described
above. Surgery was performed within the following week in 91% of
the patients. The median interval from last radiotherapy to surgery
was 4 days (3 days: 45%; 4 days: 32%; 5 days: 9%; 6–10 days: 9%;
11–25 days: 5%). In 72% of the patients, a sphincter-sparing
resection (SSR) with primary anastomosis was performed, 70% of
these were given a temporary protective stoma. In all, 81% of 100
patients receiving surgery at the Department of General Surgery at
Vienna University General Hospital had a sphincter sparing
procedure, compared to 51 (61%) of 84 patients operated at
outside departments of surgery listed in the Acknowledgements
(w
2¼4.2; DF¼1; Po0.05). In 156 patients (85%) a histologically
complete resection was achieved, 13% were rated R1, 2% (four
patients) were rated R2. As this study did not have a control group
without radiotherapy, a comparative assessment of complications
during surgery is unavailable. One patient died 8 days after surgery
from myocardial infarction. Previously undetected liver metastases
had been encountered during surgery in this patient. One other
patient acquired a respiratory distress syndrome 9 days after
surgery and died on the 43rd postoperative day in the intensive
care unit. Thus, 30-day postoperative mortality was 0.5% in this
group of patients. The Median stay in hospital after surgery was 13
days.
Recurrence
The actuarial overall rate (stages I–III) for distant or local
recurrence at 4 years was 23% (Table 2). The overall recurrence
rate was significantly different between UICC stages I, II, and III.
Only three patients suffered a local recurrence at 9, 16, and 18
months. In the last patient, liver metastases had been found at
primary surgery and local recurrence occurred during systemic
progression, the other two patients had stage II disease with local
recurrence as the first site of failure. Thus, the actuarial rate for
local recurrence after macroscopically complete resection was
2.1% at 4 years and, remarkably, no further local recurrence has
been hitherto encountered in patients with longer follow-up. All
local recurrences were presacral within the radiation field. There
was no recurrence at the perineum although the whole perineum
was not included in the radiation field, even if an APR was
planned. In four patients, a macroscopically complete resection
was not attained: in one patient the tumour was not resected and a
Hartmann situation established, in the other three patients
macroscopic tumour was left behind. All of them had T3 or T4
and all had N2 disease and they died at 2, 2, 11, and 14 months,
respectively. If these patients are included in the analysis for local
control, the actuarial local control rate is 96% at 4 years.
Survival
Median follow-up was 53 months for surviving and 43 months for
all patients, only five patients had a follow-up of less than 24
months. Actuarial overall and disease-specific survivals for all
patients at four years were 68 and 76%, respectively (Table 2).
Excluding patients with metastases encountered at surgery, overall
survival for patients at stages I–III (n¼171) at 4 years was 72%,
disease-specific survival for these patients was 82%. Disease-free
survival was 69% for patients without synchronous distant
metastases (Figure 1). Stage III conferred a significantly worse
prognosis compared to stages I and II, the difference between
stages I and II was not significant. Six of the 184 patients analysed
died more than 5 years after treatment at ages 72, 74, 74, 80, 81,
and 86. All of them succumbed to intercurrent disease, none had
signs of recurrent tumour, and none of these deaths were related to
an abdominal condition. The latest metastasis-related deaths
occurred at 48 and 56 months, respectively.
Table 2 Survival and overall recurrence rate (numbers are percentages)
DSS DFS OS RR
2y 4y 2y 4y 2y 4y 2y 4y
Stage I (n¼60) 100 92 90 86 93 84 4 5
Stage II (n¼48) 98 89 79 70 92 77 15 22*
Stage III (n¼63) 81 66** 57 52* 73 57* 36 40*
Stage I–III (n¼171) 92 82 75 69 85 72 19 23
Stage IV (n¼13) 35 0 NA NA 35 0 NA NA
All patients (n¼184) 88 76 NA NA 82 68 NA NA
NA: not applicable; DSS: disease-specific survival; DFS: disease-free survival; OS: overall survival; RR: recurrence rate (distant or local). *Po0.05; **Po0.01 calculated by log-rank
statistic.
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Figure 1 Disease-free survival.
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sAbdominal complications and adverse effects
In all, 37 patients experienced abdominal or pelvic complications
and seven deaths were related to these events (Table 3). All
anastomotic stenoses requiring dilation and anastomotic leaks
occurred within 3 months post-surgery. Pelvic infections and
pelvic bleeding requiring surgical interventions also occurred
shortly after cancer surgery. Two rectovaginal fistulae, appearing 7
days and 2 months post-surgery, respectively, were surgically
repaired. In all, 70% of patients who underwent primary colorectal
or coloanal anastomosis at tumour resection received a protective
stoma. Five patients suffered leakage at the site of reconnection
after closure of their stoma, three times this was fatal (two
ileostomies, one transversostomy). One patient developed an ileus
due to stenosis at the site of re-connection, which required surgical
revision.
Bowel function
To assess late bowel function, we report functional results at the
last follow-up 5 or more years after treatment for patients treated
in 1994–98 (n¼130). Of these, 77 were alive at final analysis with a
median follow-up of 71 months (range 60–123 months). Func-
tional data are available for 68 patients displayed in Table 4. Of
these, 22 patients had a well-functioning permanent stoma and
were assessed for pelvic pain only, 46 patients with a sphincter in
place had a full assessment of bowel function. In all, 78% reported
good quality of life. No patient but one reported problems with
micturition, this one patient was on chronic dialysis due to
intercurrent nonobstructive kidney failure. All patients assessed
reported stable bowel function within the year previous to final
assessment.
DISCUSSION
Radiotherapy used as an adjunct to radical surgery reduces the
local failure rate from rectal cancer (Camma et al, 2000; Colorectal
Cancer Collaborative Group, 2001). The 1990 NIH consensus
recommends postoperative radiotherapy combined with chemo-
therapy for patients with UICC stage II and III rectal cancer (NIH
consensus conference, 1990). A more recent expert opinion again
recommends radiotherapy to be used as an adjunct to surgery
preoperatively (short term or long term) or postoperatively (van
Cutsem et al, 2002). Local failure was reduced in the postoperative
radiotherapy arm of the NSABP protocol R-02 (8 vs 13% at
5 years), although survival was not affected by radiotherapy
(Wolmark et al, 2000). In the Swedish Rectal Cancer Trial, the
5-year actuarial local recurrence rate decreased from 27% without
to 11% with preoperative short-term radiotherapy of 25Gy, and
survival increased from 48 to 58% at 5 years in the radiotherapy-
plus-surgery arm (Swedish rectal cancer trial, 1997). More recently,
the local failure rate at 2 years after standardised and quality-
assured TME was 8.2%, but only 2.4%, if surgery was preceded by
25Gy short-term radiotherapy in the Dutch TME trial (Kapiteijn
et al, 2001).
We present the results of the first 184 consecutively treated
patients at our institution from 1994 to 2000, where 25Gy
preoperative radiotherapy was administered using two daily
fractions of 2.5Gy, approaching the conventional fraction size of
2Gy, but within an overall treatment time of 1 week in a
hyperfractionated regimen. The modification was chosen in order
to reduce the likelihood of late adverse effects. This assumption is
supported by the linear quadratic (LQ) model, the best presently
available and widely used model for the estimation of the
biologically effective radiation therapy dose (BED) (Glimelius
et al, 1997; Colorectal Cancer Collaborative Group, 2001). As
shown in Table 5b, 25Gy administered with 2.5Gy twice daily
fractions within 1 week equals a total dose of 34Gy considering the
tumour effect, if it would be delivered conventionally with 2Gy
daily fractions (see also Appendix A). Short-term 5 5Gy daily,
the treatment regimen used in Scandinavia, the United Kingdom,
the Netherlands, and elsewhere, equals 42Gy considering the
tumour effect. The conventional dose of long-term preoperative
radiotherapy for rectal cancer is 45–50Gy. Considering late
normal tissue (adverse) effects, our treatment regimen corre-
sponds to only 28Gy total dose (assuming an a/b¼3) adminis-
tered with daily 2Gy, 5 5Gy corresponds to 40Gy (other
fractionations shown in Table 5b). Given the demonstrated efficacy
for preoperative radiotherapy schedules resulting in a BED of
X30Gy10 (see Table 5a) in a recent meta-analysis (Colorectal
Cancer Collaborative Group, 2001), and given the results described
in this paper, 10 2.5Gy administered within 1 week seems to be a
treatment regimen with a very favourable risk/benefit ratio (Table
5a and b).
In our study, 78% of the patients with a median follow-up of
more than 7 years report no impairment of quality of life due to
bowel function and 80% are able to delay defecation for more than
15min upon urge. Only a minority of patients reported a high stool
frequency and disturbing clustering. Definitive conclusions cannot
be drawn from these data, although they are in agreement with
Table 3 Abdominal complications
n (%)
Of these
leading to
death
Patients with primary anastomosis 132 (100%)
Within 3 months post surgery
Stenosis requiring dilation 8 (6%) 1 (0.8%)
Anastomotic leakage 15 (11.4%) 3 (2.3%)
Recto-vaginal fistula 2 (1.5%) 0
Later than 3 months post surgery
Stenosis requiring dilation 0 0
Anastomotic leakage 0 0
Intestinal leak after closure of stoma 5 (3.8%) 3 (2.3%)
All patients 184 (100%)
Pelvic infection 7 (3.8%) 0
Pelvic bleeding 3 (1.6%) 0
Patients with abdominal and/or pelvic complications 37 (20.1%) 7 (3.8%)
Table 4 Bowel function at last follow-up 5 years or later (5–10years),
for evaluable patients treated 1994–98 (n¼68)
Good Intermeditate Bad % (n)
Quality of life 78 (36) 20 (9) 2 (1) 100 (46)
Frequency/d 24 (11) 54 (25) 22 (10) 100 (46)
Clustering 26 (12) 61 (28) 13 (6) 100 (46)
Delay upon urge 80 (37) 20 (9) 100 (46)
Distinction stool/gas 78 (36) 22 (10) 100 (46)
Tenesms 96 (43) 4 (2) 100 (46)
Wearing pads 67 (31) 33 (15) 100 (46)
Pelvic pain 100 (68) 0 100 (68)
Numbers represent percentages (n in parentheses). Primary anastomosis: 46 patients;
permanent stoma: 22 patients. Categories (from good to bad): quality of life altered
by bowel function: no – yes – significantly; stool frequency per day: p1–2–3–43;
clustering: one portion – two to three portions – more than three portions per
defecation; ability to delay defecation upon urge: 415min–o15min; ability to
distinguish between stool and gas: yes–no; experiencing tenesms: no–yes; wearing
pads because of fear of incontinence: no–yes; pelvic pain: no–yes.
25Gy preoperative radiotherapy for rectal cancer
J Widder et al
1212
British Journal of Cancer (2005) 92(7), 1209–1214 & 2005 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
spredictions derived from the LQ radiobiological model. It can
safely be said that this treatment is very likely to have a low long-
term toxicity profile besides its extremely well tolerability in the
short run. A definite conclusion regarding late toxicity would
require a prospective comparative study, however.
Three patients (2.3% of those with sphincter-sparing surgery)
died due to an intestinal leak at the site of reconnection after
closure of a protective ileostoma (two patients) or transversostoma
(one patient). The latter patient had furthermore developed
hepatic failure due to liver cirrhosis shortly after reversal, possibly
contributing to perforation. Although this number appears to be
relatively high, a relation to radiotherapy could not be found, as
the intestine used for the stoma was outside the radiation fields
and histology reports of the leaking intestines upon surgical
revision revealed no signs of radiation damage.
Swedish researchers have found an increase in bowel move-
ments after preoperative radiotherapy (25Gy, 5 5Gy) compared
to surgery alone, and more patients stated they had an impaired
social life due to bowel dysfunction (Dahlberg et al, 1998). It is
tempting to speculate that modifying the fractionation from
5 5Gy to 10 2.5Gy within the same overall treatment time
does reduce the likelihood of functionally relevant adverse late
effects in accordance with calculations derived from the LQ model.
Our results provide support that the efficacy of the short-term
25Gy preoperative regimen is maintained if it is modified to
hyperfractionation. By close collaboration between the rectal
surgeons and radiotherapists, it is possible to select patients who
are sufficiently treated by a nondownstaging short course of
preoperative radiotherapy to prevent local failure. This is presently
facilitated by using phased-array pelvic MRI (Beets-Tan et al,
2001). An actuarial local recurrence rate of 2.1% at 4 years
compares favourably with any reported recurrence rates in the
literature in comparable patients, especially in a multi-institutional
setting with regard to surgery. It needs to be kept in mind that all
patients included in this analysis were clinically diagnosed with
primarily resectable, locally moderately advanced rectal cancer.
Patients with clear clinical or radiological evidence of a small
tumour that appeared to be confined to the rectal wall and without
suspicious pelvic lymph nodes did not undergo preoperative
radiation treatment and are not included in this analysis. The fact
that 33% of the surgical specimens were postoperatively diagnosed
as stage I (T1: 6%, T2: 27%) reflects the uncertainty of diagnostic
modalities used during recruitment to this study (1994–2000) and
is in agreement with the Dutch TME trial, where 30% of the
patients had stage I disease. As 86% of the patients received
surgery within 5 days of the last fraction of radiotherapy,
downstaging is unlikely to account for the postoperative rate of
stage I tumours. On the other hand, 22% (14 of 63) of T2 tumours
had positive lymphnodes, comprising a known risk factor for local
recurrence.
Four patients were found unresectable at surgery with T3N2
(two patients, one of whom had liver metastases) and T4N2 (two
patients) tumours, an event that is likely to be preventable by the
use of pelvic MRI also. Had unresectability been assessed in
advance, these patients would not have been included in this study
but – at least those without metastases – would have been offered
preoperative long-term radiochemotherapy in order to downsize
the tumour.
Out of 224 patients operated upon for rectal cancer at the
Vienna General Hospital Department of Surgery between 1994 and
2000, 51% did not receive any radiotherapy, 44% received short-
term hyperfractionated accelerated radiotherapy to 25Gy (this
study), and 5% received long-term preoperative radiochemo-
therapy. No patient from this cohort received postoperative radio-
therapy within this period. Although the data for chemotherapy
were not analysed, all patients were offered 5-fluorouracil-based
postoperative chemotherapy at stage II–III if they were medically
fit to receive such therapy. Patients with distant metastases
received palliative multiagent chemotherapy and were offered
surgery for resectable metastases.
Short-term preoperative radiotherapy of 25Gy administered
within 1 week in 10 fractions of 2.5Gy for resectable localised
rectal cancer constitutes a well-tolerated and simple way to
increase local control, with long-term adverse effects apparently in
Table 5a BED using the linear quadratic formula
a
25Gy (10 2.5Gy) 25Gy (5 5Gy) 50Gy (25 2Gy) 45Gy (25 1.8Gy) 50.4Gy (28 1.8Gy)
Tumour, a/b¼10 OTT disregarded (Gy10) 31.3 37.5 60 53.1 59.5
Tumour, a/b¼10 OTT taken into account (Gy10) 31.3 37.5 44.4 37.5 42.1
Normal tissue, a/b¼5 (Gy5) 37.5 50 70 61.2 68.5
Normal tissue, a/b¼3 (Gy3) 45.8 66.7 83.3 72 80.6
aFor calculations see Appendix A. BED: bioloically effective dose; OTT: overall treatment time (days). For calculations disregarding and taking into account OTT, respectively, see
Appendix A. a/b: the linear quadratic quotient, set to 10 for tumour effects; set to 5 and 3 for normal tissue effects. Gy10 (Gy5 and Gy3): the biologically effective dose calculated
using an a/b of 10 (5 and 3); Equivalent total dose with 2Gy daily fractions: the equivalent total dose, if 2Gy daily fractions would be used, calculated using the linear quadratic
formula with a/b quotients as indicated. Results rounded to multiples of 2Gy fractions.
Table 5b Equivalent total doses for treatment regimens, for tumour effects and normal tissue effects, if 2Gy daily fractions would be used
a
Equivalent total dose with 2Gy
daily fractionation 25Gy (10 2.5Gy) 25Gy (5 5Gy) 50Gy (25 2Gy) 45Gy (25 1.8Gy) 50.4Gy (28 1.8Gy)
Tumour, a/b¼10 OTT disregarded (Gy) 26 32 50 44 50
Tumour, a/b¼10 OTT taken into account (Gy) 34 42 50 42 48
Normal tissue, a/b¼5 (Gy) 26 36 50 44 50
Normal tissue, a/b¼3(Gy) 28 40 50 44 48
aFor calculations see Appendix A. OTT: overall treatment time (days). For calculations disregarding and taking into account OTT, respectively, see Appendix A. a/b: the linear
quadratic quotient, set to 10 for tumour effects; set to 5 and 3 for normal tissue effects. Gy10 (Gy5 and Gy3): the biologically effective dose calculated using an a/b of 10 (5 and 3);
Equivalent total dose with 2Gy daily fractions: the equivalent total dose, if 2Gy daily fractions would be used, calculated using the linear quadratic formula with a/b quotients as
indicated. Results rounded to multiples of 2Gy fractions.
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sa quite tolerable range. This regimen seems to bring about
excellent local control without marked late morbidity in primary
resectable T3 rectal cancer, where downsizing is not deemed
necessary in order to achieve a complete resection. Prospective
comparative evaluation of this regimen seems warranted especially in
combination with new antineoplastic drugs delivered postoperatively.
ACKNOWLEDGEMENTS
We thank the following departments of surgery who have
contributed to the study: Baden, H Trapl; Hainburg, G Loncsar;
Oberpullendorf, F Hofbauer; Oberwart, K Mach; Sozialmedizinisches
Zentrum Ost, Vienna, R Schiessel; Wiener Neustadt, A Lenauer.
REFERENCES
Beets-Tan RG, Beets GL, Vliegen RF, Kessels AG, Van Boven H, De Bruine
A, von Meyenfeldt MF, Beaten CG, van Engelshoven JM (2001) Accuracy
of magnetic resonance imaging in prediction of tumour-free resection
margin in rectal cancer surgery. Lancet 357: 497–504
Camma C, Giunta M, Fiorica F, Pagliaro L, Craxi A, Cottone M (2000)
Preoperative radiotherapy for resectable rectal cancer: a meta-analysis.
JAMA 284: 1008–1015
Colorectal Cancer Collaborative Group (2001) Adjuvant radiotherapy for
rectal cancer: a systematic overview of 8507 patients from 22 randomised
trials. Lancet 358: 1291–1304, doi:10.1016/S0140-6736(01)06409-1
Dahlberg M, Glimelius B, Graf W, Pahlman L (1998) Preoperative
irradiation affects functional results after surgery for rectal cancer:
results from a randomized study. Dis Colon Rectum 41: 543–549
Dische S, Saunders M, Barrett A, Harvey A, Gibson D, Parmar M (1997) A
randomised multicentre trial of CHART versus conventional radio-
therapy in head and neck cancer. Radiother Oncol 44: 123–136,
doi:10.1016/S0167-8140(97)00094-7
Esnaola NF, Cantor SB, Johnson ML, Mirza AN, Miller AR, Curley SA,
Crane CH, Cleeland CS, Janjan NA, Skibber JM (2002) Pain and quality of
life after treatment in patients with locally recurrent rectal cancer. J Clin
Oncol 20: 4361–4367
Glimelius B (2002) Radiotherapy in rectal cancer. Br Med Bull 64: 141–157
Glimelius B, Isacsson U, Jung B, Pahlman L (1997) Radiotherapy in
addition to radical surgery in rectal cancer: evidence for a dose–
response effect favoring preoperative treatment. Int J Radiat Oncol Biol
Phys 37: 281–287
International Commission on Radiation Units and Measurement (ICRU)
(1993) Prescribing, Recording and Reporting Photon Beam Therapy. ICRU
Report No. 50. Washington, DC: ICRU
Jones B, Dale RG (1999) Mathematical models of tumour and normal tissue
response. Acta Oncol 38: 883–893, doi:10.1080/028418699432572
Kapiteijn E, Marijnen CA, Nagtegaal ID, Putter H, Steup WH, Wiggers T,
Rutten HJ, Pahlman L, Glimelius B, van Krieken JH, Leer JW, van de
Velde CJ, Dutch Colorectal Cancer Group (2001) Preoperative radio-
therapy combined with total mesorectal excision for resectable rectal
cancer. N Engl J Med 345: 638–646
MacFarlane JK, Ryall RD, Heald RJ (1993) Mesorectal excision for rectal
cancer. Lancet 341: 457–460, doi:10.1016/0140-6736(93)90207-W
NIH consensus conference (1990) Adjuvant therapy for patients with colon
and rectal cancer. JAMA 264: 1444–1450
Swedish Rectal Cancer Trial (1997) Improved survival with preoperative
radiotherapy in resectable rectal cancer. N Engl J Med 336: 980–987
Van Cutsem E, Dicato M, Wils J, Cunningham D, Diaz-Rubio E, Glimelius
B, Haller D, Johnston P, Kerr D, Koehne CH, Labianca R, Minsky B,
Nordlinger B, Roth A, Rougier P, Schmoll HJ (2002) Adjuvant treatment
of colorectal cancer (current expert opinion derived from the Third
International Conference: perspectives in colorectal cancer, Dublin,
2001). Eur J Cancer 38: 1429–1436, doi:10.1016/S0959-8049(02)00122-3
Widder J, Sedlmayer F, Stanek C, Po ¨tter R (2000) Quality assurance in
preoperative radiotherapy of rectal cancer: evaluation of a pre-trial dummy-
run. Radiother Oncol 56: 341–347, doi:10.1016/S0167-8140(00)00232-2
Wolmark N, Wieand HS, Hyams DM, Colangelo L, Dimitrov NV, Romond
EH, Wexler M, Prager D, Cruz Jr AB, Gordon PH, Petrelli NJ, Deutsch M,
Mamounas E, Wickerham DL, Fisher ER, Rockette H, Fisher B (2000)
Randomized trial of postoperative adjuvant chemotherapy with or
without radiotherapy for carcinoma of the rectum: National Surgical
Adjuvant Breast and Bowel Project Protocol R-02. J Natl Cancer Inst 92:
388–396
Appendix A
The BED is calculated using the LQ formula. The basic formula
takes into account single dose, number of fractions, and the a/b-
quotient: BED¼nd (1þd/a/b), where n is the number of fractions;
d the dose (Gy) per fraction; a/b the LQ quotient. The LQ quotient
is usually set to 10 for acute (tumour) effects, and to 3 or 5 for late
(normal tissue) effects. For late effects in normal tissue, the impact
of overall treatment time is generally not regarded relevant (Jones
and Dale, 1999). For tumour effects, the overall treatment time is
taken into account by incorporating the repair rate g/a, set to
0.6Gy per day, which is a measure for how much dose is lost per
day due to tumour tissue repair. The proliferation delay Tk, set to 7
days (Colorectal Cancer Collaborative Group, 2001), is subtracted
from the overall treatment time T, which means that, after a delay
of 7 days, repair mechanisms become relevant that lead to a loss of
tumour-damaging effects at a magnitude of 0.6Gy per day. Thus,
the formula for tumour effects taking into account the overall
treatment time (including weekends) is
BED ¼ ndð1 þ d=a=bÞ g=aðT   TkÞ;
with an a/b of 10. If the overall treatment time is shorter than the
proliferation delay Tk, the term would be negative and has
therefore to be set to 0 in these cases (the case for 5-day overall
treatment time). As repair rate and proliferation delay carry a
higher degree of uncertainty than the a/b quotient, results are also
reported for BEDs disregarding the effects of overall treatment
time in Tables 5a and 5b. It can be seen that in shorter treatment
regimens (5 days overall treatment time) the respective effect of
1Gy administered is higher for tumour than for normal tissue,
because a much smaller total dose achieves an effect upon the
tumour that would require a higher total dose, if administered over
a longer overall treatment time (Table 5b). Conventional radio-
therapy treatments are administered with daily fractions of 2Gy.
To understand the biological tumour and normal tissue effects of
unconventional fractionations such as 5 5Gyor10 2.5Gy with
two fractions administered daily, it is helpful to calculate total
doses delivered with conventional fractionation, that would be
biologically equivalent with the regimen in question. This is done
by seeking the number of fractions of 2Gy necessary to yield the
BED of the regimen in question (e.g. 10 2.5Gy), of course using
the same parameters for the a/b quotient. In this way, equivalent
total doses for different a/b quotients are obtained that can be used
to estimate the tumour and normal tissue effects of an unconven-
tional treatment regimen (Table 5b).
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